Welcome to our dedicated page for Astrotech news (Ticker: ASTC), a resource for investors and traders seeking the latest updates and insights on Astrotech stock.
Astrotech Corporation develops instrumentation businesses built around mass spectrometry and gas chromatography technologies through wholly owned subsidiaries. News about ASTC commonly covers 1st Detect and its TRACER 1000 trace detection systems for aviation security, explosives screening, and narcotics detection, including regulatory certifications, deployments, and security-market applications.
Company updates also address AgLAB process analyzers for agriculture products, Pro-Control industrial chemical process control, BreathTech breath-analysis work for volatile organic compounds, and EN-SCAN portable environmental GC-MS for field testing of air, water, and soil. Recurring releases include fiscal results, research and development progress, sales activity, leadership appointments, and board-level strategic or governance actions.
Astrotech Corporation (NASDAQ: ASTC) announced a registered direct offering of 2,887,906 shares at $2.15 each, totaling gross proceeds of $6.2 million, expected to close around October 30, 2020. H.C. Wainwright & Co. is the exclusive placement agent for the offering. The funds will be allocated to ongoing operating expenses and working capital. This offering is conducted under a previously filed shelf registration statement with the SEC.
Astrotech Corporation (NASDAQ: ASTC) announced that its subsidiary, 1st Detect, has secured over $1 million in purchase orders and similar commitments for its TRACER 1000™ explosives trace detector. This technology is currently operational at multiple DHL locations across eight countries in Europe and Asia. The TRACER 1000 is distinguished as the only certified ETD utilizing mass spectrometry, having passed rigorous testing from regulatory bodies like the ECAC and TSA. Executives highlight the growth potential in the recovering transportation sector and areas where high-performance detection is critical.
Astrotech Corporation (NASDAQ: ASTC) has successfully completed a public offering of 7,826,086 shares of common stock at $2.30 per share, generating approximately $18 million in gross proceeds.
The funds will be utilized for ongoing operating expenses and working capital. H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The shares were offered under two SEC registration statements, providing a compliant pathway for this capital raise.
Astrotech Corporation (Nasdaq: ASTC) has announced the pricing of a public offering of 7,826,086 shares of common stock at $2.30 per share, expecting gross proceeds of approximately $18 million. The offering is anticipated to close around October 23, 2020, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. Proceeds will be used for ongoing operating expenses and working capital. The securities are offered under effective registration statements filed with the SEC.
Astrotech Corporation's subsidiary, BreathTech Corporation, has signed a joint development agreement with Cleveland Clinic to enhance the BreathTest-1000™ mass spectrometer for rapid COVID-19 screening. This partnership aims to create a non-invasive device that identifies COVID-19 strains from breath samples, potentially providing a low-cost, large-scale screening solution. The clinical trial with the technology is expected to commence soon, leveraging the expertise of Dr. Raed Dweik and his research team in detecting diseases through breath analysis.